Latest Breaking News On - சுரேஷ் சிங் - Page 8 : comparemela.com

Give us vaccine choice: Swadeshi Covaxin can bring down number of symptomatic Covid cases By Dr Suresh Singh With around 2.61 crore vaccinated since 1st phase on January 16, 2021, against a target of 30 crore people, only time will tell how and when about 60-70per cent of population will have a semblance of community immunity. As a doctor, if one gives me preference, I will choose Covaxin against Covishield for the reasons stated below. This does not mean that I will reject Covishield. It is a whole-virion inactivated form, this simply means that it will have less side effects. It has 81 per cent interim efficacy in phase-3 trial evolving a huge 25,800 volunteers across the country. Covishield has 53per cent efficacy when given 2nd dose in less than 6 weeks after 1st shoot (AstraZeneca –University of Oxford based report). But efficacy varies with gap between 1st and 2nd dose of injection. World is divided too much on Covishield.

Uttar pradeshUnited statesSouth africaSuresh singhNarendra modiAatmanirbhar bharat covaxinUniversity of oxfordFinancial express indiaSwadeshi covaxinBharat biotechDistrict immunization officerAatmanirbhar bharatPrime minister narendra modiஉத்தர் பிரதேஷ்ஒன்றுபட்டது மாநிலங்களில்சுரேஷ் சிங்